Quarterly report pursuant to Section 13 or 15(d)

LICENSED TECHNOLOGY (Details Narrative)

v3.20.2
LICENSED TECHNOLOGY (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Apr. 02, 2020
Nov. 04, 2018
May 15, 2015
Jun. 30, 2020
Mar. 31, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Apr. 17, 2020
Dec. 31, 2019
Indefinite-lived Intangible Assets [Line Items]                    
Due to licensor current       $ 28,800,000     $ 28,800,000     $ 27,400,000
Guaranteed and payable $ 20,000,000                  
Royalties payments $ 8,000,000                  
License to be paid   $ 3,000,000             $ 8,000,000  
Interest payable   1,000,000                
Debt Instrument, Maturity Date Nov. 04, 2020                  
Debt Instrument, Periodic Payment, Principal             28,000,000      
Debt Instrument, Increase, Accrued Interest             800,000      
Non-cash licensed technology impairment charge       $ 32,900,000 32,916,000    
Amortization of intangible assets       $ 44,000   $ 1,293,000 1,338,000 $ 2,638,000    
Abeona Therapeutics LLC [Member]                    
Indefinite-lived Intangible Assets [Line Items]                    
Finite-lived intangible asset, useful life     20 years              
Original License Agreements [Member]                    
Indefinite-lived Intangible Assets [Line Items]                    
License to be paid   10,000,000                
Amended Agreements [Member] | April 1, 2020 [Member]                    
Indefinite-lived Intangible Assets [Line Items]                    
License to be paid   8,000,000                
REGENXBIO [Member]                    
Indefinite-lived Intangible Assets [Line Items]                    
Due remains value             $ 28,000,000      
REGENXBIO [Member] | Licensing Agreements [Member]                    
Indefinite-lived Intangible Assets [Line Items]                    
Royalty fees   180,000,000                
Guaranteed upfront payment   20,000,000                
Payment on Execution of Contracts   10,000,000                
Due to licensor current   10,000,000                
Guaranteed and payable   20,000,000                
Royalties payments   $ 60,000,000                
Finite-lived intangible asset, useful life   8 years                
REGENXBIO [Member] | Licensing Agreements [Member] | Maximum [Member]                    
Indefinite-lived Intangible Assets [Line Items]                    
Annual fees   $ 100,000,000